



## Neurotoxins (Botox®, Dysport®, Myobloc® and Xeomin®)

Last Review Date: November 11, 2016

Number: MG.MM.PH.01m

### Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### Definition

Neurotoxins (referred to in this guideline collectively as musculoskeletal agents) are produced by Clostridium botulinum. There are seven known serotypes; out of these, only A and B are approved medicinally.

Musculoskeletal agents produce a presynaptic neuromuscular blockade by preventing the release of acetylcholine from the nerve endings, which results in the chemical denervation of muscle causing local paresis or paralysis.

Selected muscles such as these can be treated — overactive skeletal muscles (e.g. hemifacial spasm, dystonia, and spasticity), smooth muscles (e.g. detrusor overactivity and achalasia), glands (e.g. sialorrhea and hyperhidrosis); others are currently being investigated (see also [Off-Label Use of FDA-Approved Drug and Biologics guidelines](#))

There are four commercially available products in the United States; each with distinct pharmacological and clinical profiles, as well as dosing patterns.

Agent	Prescribing Information
A. <a href="#">Botox®</a> (onabotulinumtoxinA)	<a href="http://www.allergan.com/assets/pdf/botox_pi.pdf">http://www.allergan.com/assets/pdf/botox_pi.pdf</a>
A. <a href="#">Dysport™</a> (abobotulinumtoxinA)	<a href="http://www.galdermausa.com/IFU/Dysport_IFU.pdf?_ga=1.205661723.920858028.1472140306">http://www.galdermausa.com/IFU/Dysport_IFU.pdf?_ga=1.205661723.920858028.1472140306</a>
B. <a href="#">Myobloc®</a> (rimabotulinumtoxinB)	<a href="http://www.myobloc.com/myobloc/hp_about/PI_5-19-10.pdf">http://www.myobloc.com/myobloc/hp_about/PI_5-19-10.pdf</a>
C. <a href="#">Xeomin®</a> (incobotulinumtoxinA)	<a href="http://www.xeominaesthetic.com/wp-content/uploads/XEOMIN-Prescribing-Information.pdf">http://www.xeominaesthetic.com/wp-content/uploads/XEOMIN-Prescribing-Information.pdf</a>

### Related Medical Guideline

[Off-Label Use of FDA-Approved Drugs and Biologics](#)

### Guideline

Members ≥ 18 years of age (or unless otherwise specified) are eligible for coverage of musculoskeletal agents per the criteria below.

**A. Botox® — any:**

1. Blepharospasms ( $\geq 12$  years of age)
2. Cervical dystonia ( $\geq 16$ ) to reduce the severity of abnormal head position and neck pain.
3. Strabismus in members ( $\geq 12$ )
4. Lower limb spasticity
5. Upper limb spasticity
6. Severe palmar hyperhidrosis — both:
  - a. Failure of topical agents and pharmacotherapy (unless contraindicated)
  - b. History of medical complications (e.g., skin infections/functional impairments) or significant impact to activities of daily living (directly attributable to the condition).
7. Severe primary axillary hyperhidrosis — both:
  - a. Failure of topical agents and pharmacotherapy (unless contraindicated)
  - b. History of medical complications (e.g., skin infections/functional impairments) or significant impact to activities of daily living (directly attributable to the condition).
8. Chronic daily headache (migraine or tension-type) — all:
  - a. Frequency  $> 15$  days a month
  - b. Duration  $\geq 4$  hours for  $\geq 3$ -month period
  - c. Failure of  $\geq 2$ -month trial of oral pharmacotherapy (e.g., antidepressants, anti-epileptics, angiotensin converting enzyme inhibitors, beta/calcium channel blockers, etc.) unless contraindicated
9. Esophageal achalasia — any:
  - a. High risk of complication from pneumatic dilation or surgical myotomy
  - b. Failed pneumatic dilation or surgical myotomy
  - c. Perforation attributable to pneumatic dilation
  - d. Presence of epiphrenic diverticulum or hiatal hernia
  - e. Presence of esophageal varices
10. Oromandibular dystonia
11. Laryngeal dystonia
12. Cerebral palsy with concurrent equinus gait
13. Sialorrhea — failure of oral therapy in the presence of any:
  - a. Severe developmental delays
  - b. Cerebral palsy
  - c. Parkinson's disease
  - d. ALS secondary to other neurological disorders
14. Urinary incontinence due to detrusor overactivity — failed or intolerant to anticholinergic medication
15. Overactive bladder — with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication
16. Focal upper limb dystonia with either pain or functional impairment
17. Idiopathic (primary or genetic) torsion and symptomatic (acquired) torsion dystonia
18. Hereditary spastic paraplegia
19. Infantile cerebral palsy
20. Spasticity due to multiple sclerosis

21. Neuromyelitis optica
22. Schilder's disease
23. Spastic hemiplegia
24. Chronic anal fissure — failed conventional therapy
25. Idiopathic transverse myelitis
26. Quadriplegia
27. Paraplegia
28. Diplegia of upper limbs
29. Monoplegia
30. Spastic ENT/ectropion
31. Hemiplegia
32. Hemifacial spasm
33. Other paralytic syndromes

**B. Dysport™** — ≥ 18 years of age and either:

1. Cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naïve and previously treated patients
2. Blepharospasm
3. Spasticity due to cerebral palsy
4. Hemifacial spasm
5. Lower limb spasticity in pediatric patients (> 2 years of age)

**C. Myobloc®** — any:

1. Cervical dystonia (in adults) to reduce the severity of abnormal head position and neck pain associated with cervical dystonia
2. Bladder muscle dysfunction
3. Excessive salivation

**D. Xeomin®** — ≥ 18 years of age and either:

1. Cervical dystonia (in adults) to decrease the severity of abnormal head position and neck pain in both toxin-naïve and previously treated patients
2. Blepharospasm
3. Upper limb spasticity

---

## Documentation

The following elements must be made available to the plan upon request:

- ✓ Dosage and frequency
- ✓ Support of clinical effectiveness/medical necessity
- ✓ Support of medical necessity for electromyography procedures to determine injection site location
- ✓ Specification of injection site(s)
- ✓ Post-session results and treatment response.

---

## Utilization/Limitations

- ✓ Electromyography or muscle stimulation, rather than site pain or tenderness, to determine injection site(s) may be necessary, especially for spastic conditions of the face, neck, and upper extremity.
- ✓ The plan will allow payment for one injection per site regardless of the number of injections made into the site.

- ✓ A site is defined as one eye (including all muscles surrounding the eye including both upper and lower lids); one side of the face; the neck; or the trunk and all limbs and their associated girdle muscles.
- ✓ It is generally not considered medically necessary to give musculoskeletal agents more frequently than every 90 days for spastic or excess muscular contraction conditions. With a positive response, the effect generally lasts for 3 months, at which time repeat injections to control the spastic or excessive muscular condition may be warranted.
- ✓ Failure of two definitive, consecutive, treatment sessions involving a muscle or group of muscles could preclude further coverage of the serotype used in the treatment for a period of one year after the second session. It may be reasonable, however, to attempt treatment with a different serotype.
- ✓ For certain spastic conditions (e.g., cerebral palsy, stroke, head trauma, spinal cord injuries and multiple sclerosis), coverage will be limited to those conditions listed in the diagnostic coding section. All other uses in the treatment of other types of spasm (including smooth muscle types) will be considered investigational and therefore not covered (except where included in the list of covered indications in the coding section).
- ✓ For blepharospasm, if the upper and lower lid of the same eye or adjacent facial muscles or brow is injected with an agent at the same surgery, the procedure is considered to be unilateral. Procedures will only be considered bilateral when both eyes or both sides of the face are injected.

---

## Exclusions

1. Injections exceeding the frequencies depicted in the [Utilization](#) section are not considered medically necessary.
2. Agents used for cosmetic purposes (e.g., wrinkles) are not considered medically necessary (see also [Cosmetic Surgery Procedures](#))
3. Treatment of the following conditions is not considered medically necessary, as there is insufficient evidence to support effectiveness:
  - a. Spastic conditions not listed in the ICD-9 table.
  - b. Biliary dyskinesia
  - c. Irritable bowel
  - d. Pain conditions not associated with spasticity/dystonia to include myofascial pain and fibromyalgia.
  - e. Plantar hyperhidrosis
  - f. Wrinkles

## Revision History

11/11/2016	Added presence of ALS secondary to other neurological disorders to Sialorrhea indication criteria for Botox Added criteria for palmar hyperhidrosis
8/24/2016	Added upper limb spasticity to Xeomin
8/12/16	Added lower limb spasticity in pediatric patients (> 2 years of age) to Dysport criteria
3/2/16	The following paragraph (in the “Utilization/Limitations” section pertaining to spasticity) has been corrected to add “upper extremity” — Electromyography or muscle stimulation, rather than site pain or tenderness, to determine injection site(s) for Botulinum toxin may be necessary, especially for spastic conditions of the face, neck, and upper extremity
1/21/16	Added lower limb spasticity as covered indication for Botox

## Applicable Procedure Codes

31513	Laryngoscopy, indirect; with vocal cord injection
31570	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic;
31571	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic; with operating microscope or telescope
43201	Esophagoscopy, rigid or flexible, transoral; with directed submucosal injection(s), any substance
43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance

46505	Chemodenervation of internal anal sphincter
52287	Cystourethroscopy, with injection(s) for chemodenervation of the bladder New code effective date 01/01/2013
53899	Unlisted procedure, urinary system
64611	Chemodenervation of parotid and submandibular salivary glands, bilateral
64612	Chemodenervation of muscle(s); muscle(s) innervated by facial nerve (eg, for blepharospasm, hemifacial spasm)
64615	Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)
64616	Chemodenervation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral (eg, for cervical dystonia, spasmodic torticollis) (new code effective 01/01/2014)
64617	Chemodenervation of muscle(s); larynx, unilateral, percutaneous (eg, for spasmodic dysphonia), includes guidance by needle electromyography, when performed (new code effective 01/01/2014)
64642	Chemodenervation of one extremity; 1-4 muscle(s)
64643	Chemodenervation of one extremity; each additional extremity, 1-4 muscle(s) (list separately in addition to code for primary procedure)
64644	Chemodenervation of one extremity; 5 or more muscles
64645	Chemodenervation of one extremity; each additional extremity, 5 or more muscles (list separately in addition to code for primary procedure)
64646	Chemodenervation of trunk muscle(s); 1-5 muscle(s)
64647	Chemodenervation of trunk muscle(s); 6 or more muscle(s)
64650	Chemodenervation of eccrine glands; both axillae
64653	Chemodenervation of eccrine glands; other area(s) (eg, scalp, face, neck), per day
67345	Chemodenervation of extraocular muscle
J0585	Injection, onabotulinumtoxina, 1 unit
J0586	Injection, abobotulinumtoxina, 5 units
J0587	Injection, rimabotulinumtoxinb, 100 units
J0588	Injection, incobotulinumtoxin a, 1 unit

### Applicable ICD-10 Diagnosis Codes

G04.1	Tropical spastic paraplegia
G11.4	Hereditary spastic paraplegia
G24.09	Other drug induced dystonia
G24.1	Genetic torsion dystonia
G24.2	Idiopathic nonfamilial dystonia
G24.3	Spasmodic torticollis
G24.4	Idiopathic orofacial dystonia
G24.5	Blepharospasm
G24.8	Other dystonia
G24.9	Dystonia, unspecified
G25.89	Other specified extrapyramidal and movement disorders
G35	Multiple sclerosis
G36.0	Neuromyelitis optica [Devic]
G36.1	Acute and subacute hemorrhagic leukoencephalitis [Hurst]
G36.8	Other specified acute disseminated demyelination

G36.9	Acute disseminated demyelination, unspecified
G37.0	Diffuse sclerosis of central nervous system
G37.1	Central demyelination of corpus callosum
G37.2	Central pontine myelinolysis
G37.3	Acute transverse myelitis in demyelinating disease of central nervous system
G37.4	Subacute necrotizing myelitis of central nervous system
G37.5	Concentric sclerosis [Balo] of central nervous system
G37.8	Other specified demyelinating diseases of central nervous system
G37.9	Demyelinating disease of central nervous system, unspecified
G43.019	Migraine without aura, intractable, without status migrainosus
G43.119	Migraine with aura, intractable, without status migrainosus
G43.701	Chronic migraine without aura, not intractable, with status migrainosus
G43.709	Chronic migraine without aura, not intractable, without status migrainosus
G43.711	Chronic migraine without aura, intractable, with status migrainosus
G43.719	Chronic migraine without aura, intractable, without status migrainosus
G43.901	Migraine, unspecified, not intractable, with status migrainosus
G43.909	Migraine, unspecified, not intractable, without status migrainosus
G43.911	Migraine, unspecified, intractable, with status migrainosus
G43.919	Migraine, unspecified, intractable, without status migrainosus
G44.221	Chronic tension-type headache, intractable
G44.229	Chronic tension-type headache, not intractable
G51.2	Melkersson's syndrome
G51.3	Clonic hemifacial spasm
G51.4	Facial myokymia
G51.8	Other disorders of facial nerve
G80.0	Spastic quadriplegic cerebral palsy
G80.1	Spastic diplegic cerebral palsy
G80.2	Spastic hemiplegic cerebral palsy
G80.3	Athetoid cerebral palsy
G80.4	Ataxic cerebral palsy
G80.8	Other cerebral palsy
G80.9	Cerebral palsy, unspecified
G81.10	Spastic hemiplegia affecting unspecified side
G81.11	Spastic hemiplegia affecting right dominant side
G81.12	Spastic hemiplegia affecting left dominant side
G81.13	Spastic hemiplegia affecting right nondominant side
G81.14	Spastic hemiplegia affecting left nondominant side
G82.20	Paraplegia, unspecified
G82.21	Paraplegia, complete
G82.22	Paraplegia, incomplete
G82.50	Quadriplegia, unspecified

G82.51	Quadriplegia, C1-C4 complete
G82.52	Quadriplegia, C1-C4 incomplete
G82.53	Quadriplegia, C5-C7 complete
G82.54	Quadriplegia, C5-C7 incomplete
G83.0	Diplegia of upper limbs
G83.10	Monoplegia of lower limb affecting unspecified side
G83.11	Monoplegia of lower limb affecting right dominant side
G83.12	Monoplegia of lower limb affecting left dominant side
G83.13	Monoplegia of lower limb affecting right nondominant side
G83.14	Monoplegia of lower limb affecting left nondominant side
G83.20	Monoplegia of upper limb affecting unspecified side
G83.21	Monoplegia of upper limb affecting right dominant side
G83.22	Monoplegia of upper limb affecting left dominant side
G83.23	Monoplegia of upper limb affecting right nondominant side
G83.24	Monoplegia of upper limb affecting left nondominant side
H02.041	Spastic entropion of right upper eyelid
H02.042	Spastic entropion of right lower eyelid
H02.043	Spastic entropion of right eye, unspecified eyelid
H02.044	Spastic entropion of left upper eyelid
H02.045	Spastic entropion of left lower eyelid
H02.046	Spastic entropion of left eye, unspecified eyelid
H02.049	Spastic entropion of unspecified eye, unspecified eyelid
H02.141	Spastic ectropion of right upper eyelid
H02.142	Spastic ectropion of right lower eyelid
H02.143	Spastic ectropion of right eye, unspecified eyelid
H02.144	Spastic ectropion of left upper eyelid
H02.145	Spastic ectropion of left lower eyelid
H02.146	Spastic ectropion of left eye, unspecified eyelid
H02.149	Spastic ectropion of unspecified eye, unspecified eyelid
H49.00	Third [oculomotor] nerve palsy, unspecified eye
H49.01	Third [oculomotor] nerve palsy, right eye
H49.02	Third [oculomotor] nerve palsy, left eye
H49.03	Third [oculomotor] nerve palsy, bilateral
H49.10	Fourth [trochlear] nerve palsy, unspecified eye
H49.11	Fourth [trochlear] nerve palsy, right eye
H49.12	Fourth [trochlear] nerve palsy, left eye
H49.13	Fourth [trochlear] nerve palsy, bilateral
H49.20	Sixth [abducent] nerve palsy, unspecified eye
H49.21	Sixth [abducent] nerve palsy, right eye
H49.22	Sixth [abducent] nerve palsy, left eye
H49.23	Sixth [abducent] nerve palsy, bilateral

H49.30	Total (external) ophthalmoplegia, unspecified eye
H49.31	Total (external) ophthalmoplegia, right eye
H49.32	Total (external) ophthalmoplegia, left eye
H49.33	Total (external) ophthalmoplegia, bilateral
H49.40	Progressive external ophthalmoplegia, unspecified eye
H49.41	Progressive external ophthalmoplegia, right eye
H49.42	Progressive external ophthalmoplegia, left eye
H49.43	Progressive external ophthalmoplegia, bilateral
H49.881	Other paralytic strabismus, right eye
H49.882	Other paralytic strabismus, left eye
H49.883	Other paralytic strabismus, bilateral
H49.889	Other paralytic strabismus, unspecified eye
H49.9	Unspecified paralytic strabismus
H50.00	Unspecified esotropia
H50.011	Monocular esotropia, right eye
H50.012	Monocular esotropia, left eye
H50.021	Monocular esotropia with A pattern, right eye
H50.022	Monocular esotropia with A pattern, left eye
H50.031	Monocular esotropia with V pattern, right eye
H50.032	Monocular esotropia with V pattern, left eye
H50.041	Monocular esotropia with other noncomitancies, right eye
H50.042	Monocular esotropia with other noncomitancies, left eye
H50.05	Alternating esotropia
H50.06	Alternating esotropia with A pattern
H50.07	Alternating esotropia with V pattern
H50.08	Alternating esotropia with other noncomitancies
H50.10	Unspecified exotropia
H50.111	Monocular exotropia, right eye
H50.112	Monocular exotropia, left eye
H50.121	Monocular exotropia with A pattern, right eye
H50.122	Monocular exotropia with A pattern, left eye
H50.131	Monocular exotropia with V pattern, right eye
H50.132	Monocular exotropia with V pattern, left eye
H50.141	Monocular exotropia with other noncomitancies, right eye
H50.142	Monocular exotropia with other noncomitancies, left eye
H50.15	Alternating exotropia
H50.16	Alternating exotropia with A pattern
H50.17	Alternating exotropia with V pattern
H50.18	Alternating exotropia with other noncomitancies
H50.21	Vertical strabismus, right eye
H50.22	Vertical strabismus, left eye



H50.30	Unspecified intermittent heterotropia
H50.311	Intermittent monocular esotropia, right eye
H50.312	Intermittent monocular esotropia, left eye
H50.32	Intermittent alternating esotropia
H50.331	Intermittent monocular exotropia, right eye
H50.332	Intermittent monocular exotropia, left eye
H50.34	Intermittent alternating exotropia
H50.40	Unspecified heterotropia
H50.411	Cyclotropia, right eye
H50.412	Cyclotropia, left eye
H50.42	Monofixation syndrome
H50.43	Accommodative component in esotropia
H50.50	Unspecified heterophoria
H50.51	Esophoria
H50.52	Exophoria
H50.53	Vertical heterophoria
H50.54	Cyclophoria
H50.55	Alternating heterophoria
H50.60	Mechanical strabismus, unspecified
H50.611	Brown's sheath syndrome, right eye
H50.612	Brown's sheath syndrome, left eye
H50.69	Other mechanical strabismus
H50.811	Duane's syndrome, right eye
H50.812	Duane's syndrome, left eye
H50.89	Other specified strabismus
H50.9	Unspecified strabismus
H51.0	Palsy (spasm) of conjugate gaze
H51.11	Convergence insufficiency
H51.12	Convergence excess
H51.20	Internuclear ophthalmoplegia, unspecified eye
H51.21	Internuclear ophthalmoplegia, right eye
H51.22	Internuclear ophthalmoplegia, left eye
H51.23	Internuclear ophthalmoplegia, bilateral
H51.8	Other specified disorders of binocular movement
H51.9	Unspecified disorder of binocular movement
I69.031	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.032	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.033	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.034	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
I69.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting unspecified side
I69.051	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side

169.041	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right dominant side
169.042	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left dominant side
169.043	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
169.044	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
169.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting unspecified side
169.052	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side
169.053	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
169.054	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
169.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side
169.061	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right dominant side
169.062	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left dominant side
169.063	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
169.064	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
169.065	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage, bilateral
169.069	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting unspecified side
169.131	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side
169.132	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side
169.133	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side
169.134	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side
169.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified side
169.151	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side
169.152	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side
169.153	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side
169.154	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left non-dominant side
169.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting unspecified side
169.161	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right dominant side
169.162	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left dominant side
169.163	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right non-dominant side
169.164	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left non-dominant side
169.165	Other paralytic syndrome following nontraumatic intracerebral hemorrhage, bilateral
169.169	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting unspecified side
169.231	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side
169.232	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side
169.233	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side
169.234	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side
169.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting unspecified side
169.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side
169.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side
169.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side
169.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side
169.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting unspecified side

169.261	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right dominant side
169.262	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left dominant side
169.263	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right non-dominant side
169.264	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left non-dominant side
169.265	Other paralytic syndrome following other nontraumatic intracranial hemorrhage, bilateral
169.269	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting unspecified side
169.331	Monoplegia of upper limb following cerebral infarction affecting right dominant side
169.332	Monoplegia of upper limb following cerebral infarction affecting left dominant side
169.333	Monoplegia of upper limb following cerebral infarction affecting right non-dominant side
169.334	Monoplegia of upper limb following cerebral infarction affecting left non-dominant side
169.339	Monoplegia of upper limb following cerebral infarction affecting unspecified side
169.351	Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side
169.352	Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side
169.353	Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant side
169.354	Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side
169.359	Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side
169.361	Other paralytic syndrome following cerebral infarction affecting right dominant side
169.362	Other paralytic syndrome following cerebral infarction affecting left dominant side
169.363	Other paralytic syndrome following cerebral infarction affecting right non-dominant side
169.364	Other paralytic syndrome following cerebral infarction affecting left non-dominant side
169.365	Other paralytic syndrome following cerebral infarction, bilateral
169.369	Other paralytic syndrome following cerebral infarction affecting unspecified side
169.831	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side
169.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side
169.833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-dominant side
169.834	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side
169.839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side
169.851	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side
169.852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side
169.853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side
169.854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side
169.859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side
169.861	Other paralytic syndrome following other cerebrovascular disease affecting right dominant side
169.862	Other paralytic syndrome following other cerebrovascular disease affecting left dominant side
169.863	Other paralytic syndrome following other cerebrovascular disease affecting right non-dominant side
169.864	Other paralytic syndrome following other cerebrovascular disease affecting left non-dominant side
169.865	Other paralytic syndrome following other cerebrovascular disease, bilateral
169.869	Other paralytic syndrome following other cerebrovascular disease affecting unspecified side
169.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right dominant side
169.932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side
169.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side

169.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side
169.939	Monoplegia of upper limb following unspecified cerebrovascular disease affecting unspecified side
169.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side
169.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side
169.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right non-dominant side
169.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left non-dominant side
169.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting unspecified side
169.961	Other paralytic syndrome following unspecified cerebrovascular disease affecting right dominant side
169.962	Other paralytic syndrome following unspecified cerebrovascular disease affecting left dominant side
169.963	Other paralytic syndrome following unspecified cerebrovascular disease affecting right non-dominant side
169.964	Other paralytic syndrome following unspecified cerebrovascular disease affecting left non-dominant side
169.965	Other paralytic syndrome following unspecified cerebrovascular disease, bilateral
169.969	Other paralytic syndrome following unspecified cerebrovascular disease affecting unspecified side
J38.5	Laryngeal spasm
K11.7	Disturbances of salivary secretion
K22.0	Achalasia of cardia
K60.0	Acute anal fissure
K60.1	Chronic anal fissure
K60.2	Anal fissure, unspecified
L74.510	Primary focal hyperhidrosis, axilla
L74.511	Primary focal hyperhidrosis, face
L74.512	Primary focal hyperhidrosis, palms
L74.513	Primary focal hyperhidrosis, soles
L74.519	Primary focal hyperhidrosis, unspecified
M43.6	Torticollis
M62.40	Contracture of muscle, unspecified site
M62.411	Contracture of muscle, right shoulder
M62.412	Contracture of muscle, left shoulder
M62.419	Contracture of muscle, unspecified shoulder
M62.421	Contracture of muscle, right upper arm
M62.422	Contracture of muscle, left upper arm
M62.429	Contracture of muscle, unspecified upper arm
M62.431	Contracture of muscle, right forearm
M62.432	Contracture of muscle, left forearm
M62.439	Contracture of muscle, unspecified forearm
M62.441	Contracture of muscle, right hand
M62.442	Contracture of muscle, left hand
M62.449	Contracture of muscle, unspecified hand
M62.451	Contracture of muscle, right thigh
M62.452	Contracture of muscle, left thigh
M62.459	Contracture of muscle, unspecified thigh

M62.461	Contracture of muscle, right lower leg
M62.462	Contracture of muscle, left lower leg
M62.469	Contracture of muscle, unspecified lower leg
M62.471	Contracture of muscle, right ankle and foot
M62.472	Contracture of muscle, left ankle and foot
M62.479	Contracture of muscle, unspecified ankle and foot
M62.48	Contracture of muscle, other site
M62.49	Contracture of muscle, multiple sites
M62.830	Muscle spasm of back
M62.831	Muscle spasm of calf
M62.838	Other muscle spasm
N31.0	Uninhibited neuropathic bladder, not elsewhere classified
N31.1	Reflex neuropathic bladder, not elsewhere classified
N31.8	Other neuromuscular dysfunction of bladder
N31.9	Neuromuscular dysfunction of bladder, unspecified
N32.81	Overactive bladder
N36.44	Muscular disorders of urethra
N39.3	Stress incontinence (female) (male)
N39.41	Urge incontinence
N39.42	Incontinence without sensory awareness
N39.43	Post-void dribbling
N39.44	Nocturnal enuresis
N39.45	Continuous leakage
N39.46	Mixed incontinence
N39.490	Overflow incontinence
N39.498	Other specified urinary incontinence
R32	Unspecified urinary incontinence
R35.0	Frequency of micturition
R39.15	Urgency of urination

## References

Botox [package insert]. Irvine, CA: Allergan; January, 2016.

Dysport [package insert]. Scottsdale, AZ: Medicis Pharmaceutical Corporation; July 2015.

Myobloc [package insert]. San Francisco, CA: Solstice Neurosciences, Inc; May 2010.

Xeomin (incobotulinumtoxinA) package insert. Greensboro, NC: Merz Pharmaceuticals, LLC; December 2015.

NGS Medicare Local Coverage Determination (LCD) for Botulinum Toxins (L26841). September 2014. [http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=26841&ContrId=300&ver=93&ContrVer=1&CntrctrSelected=300\\*1&Cntrctr=300&name=National+Government+Services%2c+Inc.+%28National+Government+Services%2c+Inc.+%2813202%2c+A+and+B+and+HHH+MA](http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=26841&ContrId=300&ver=93&ContrVer=1&CntrctrSelected=300*1&Cntrctr=300&name=National+Government+Services%2c+Inc.+%28National+Government+Services%2c+Inc.+%2813202%2c+A+and+B+and+HHH+MA). Accessed April 14, 2015.

Specialty-matched clinical peer review.